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Historically the development of anticancer treatments has been focused on their effect on tumor cells alone. However, newer
treatments have shifted attention to targets on immune cells, resulting in dramatic responses.The effect of DNA repair deficiency on
the microenvironment remains an area of key interest. Moreover, established therapies such as DNA damaging treatments such as
chemotherapy and PARP inhibitors further modify the tumormicroenvironment. Here we describe DNA repair pathways in breast
cancer and activation of innate immune pathways in DNA repair deficiency, in particular, the STING (STimulator of INterferon
Genes) pathway. Breast tumors with DNA repair deficiency are associated with upregulation of immune checkpoints including
PD-L1 (Programmed Death Ligand-1) and may represent a target population for single agent or combination immunotherapy
treatment.
1. Introduction
Each individual cell endures hundreds of thousands of insults
to its DNA each day [1]. Genomic instability is a pervasive
feature associated with tumor cells and is the result of an
accumulation of DNA damage within a cell [2]. Damage to
DNA is triggered by many factors such as the generation of
reactive oxidative species during metabolism (endogenous
damage) and exposure to harmful environmental stimuli
such as cigarette smoke or chemotherapy (exogenous dam-
age) [3]. Efficient DNA damage responses such as cell cycle
arrest and repair are therefore essential in order to maintain
genomic integrity and stability [2].
DNA repair deficiency, in particular defects affecting
the homologous recombination and Fanconi Anemia/BRCA
repair pathway, is estimated to occur in 25% of breast
cancers [4]. Notably, an estimated 60–69% of triple negative
breast cancers (with absence of oestrogen receptor (ER)
progesterone receptor (PR) as well as nonamplified HER2)
are reported to have a defect in DNA repair, with features
in common with BRCA1/2 mutated tumors described as
“BRCAness” [5, 6].
Although loss of DNA repair pathways can result in
tumor development, they can be exploited using targeted
therapies. Moreover, the interaction of DNA damage with
immune system activation and evasion provides novel thera-
peutic opportunities.
The roles of the host immune system and tumor
microenvironment are now recognised as being crucial to
the response to anticancer therapy [7]. The presence of
infiltrating lymphocytes has been associated with improved
outcomes in breast, ovarian, lung, colorectal and oropharyn-
geal cancers, and melanoma [8–11]. Notably triple negative
breast cancer (TNBC) has been correlated with higher levels
of lymphocytic infiltration compared to other subtypes of
breast cancer [12]. Expression of the immune checkpoint
Programmed cell Death Ligand-1 (PD-L1) is also increased
in TNBC compared to non-TNBC [13].
The IMpassion130 study of the PD-L1 targeting antibody
atezolizumab in combination with nab-paclitaxel demon-
strated a significant improvement in overall survival in
PD-L1 positive TNBC (22.0 vs 15.5 months) indicating the
potential clinical impact of exploiting immunotherapies in
this subgroup of breast cancer [14]. However, responses to
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immunotherapy are not restricted to TNBC, with responses
observed in the neoadjuvant setting in both TNBC and
hormone-receptor positive breast cancer [15], and in PD-L1
positive trastuzumab-resistant HER2 positive breast cancer
[16].
A deeper understanding of the interconnectivity between
DNA repair deficiency and immune response will enable
rational trial design of single agent and combination immune
checkpoint targeting therapies. Here we discuss how tumor
cell intrinsic immune responses to loss of DNA repair
result in modification of the tumor microenvironment and
are associated with lymphocytic infiltration. In addition,
chronic stimulation of immune pathways as a result of DNA
repair deficiency favours an immunosuppressive microenvi-
ronment, with immune checkpoint upregulation, and may
predict response to immune checkpoint blockade.
2. DNA Damage Repair Pathways
A series of interconnecting pathways exist within cells which
function to repair DNA damage [17]. Although the DNA
damage response is composed of different repairmechanisms
which target distinct types of damage, they all encompass
similar coordinated processes to detect DNA damage, recruit
repair factors at the site, and then physically repair the
damaged DNA [17].
In cancer cells, DNA repair mechanisms can be dysfunc-
tional which leaves cells dependent on remaining pathways
and therefore particularly vulnerable to therapies which
target these specific pathways (Table 1) [18].
2.1. Base Excision Repair. Subtle changes to DNA such as
single-strand breaks (SSBs) are repaired via the base excision
repair (BER) mechanism [19].This method of repair involves
the removal of damaged bases form the double helix and the
excision of the damaged section from theDNA structure [19].
Single nucleotide polymorphisms (SNPs) in members of the
base excision repair pathway, XRCC1 and APE1, have been
reported as contributing to increased risk of breast cancer,
although population studies have not yielded consistent
results [20, 21].
2.2. Nucleotide Excision Repair. Nucleotide excision repair
(NER) is the mechanism responsible for the repair of single-
strand lesions which cause a structural distortion within
the DNA double helix [22]. Nucleotides surrounding the
damaged site are excised and replaced by DNA replication
machinery [17]. Defects in NER have been identified in
early stage breast cancer and also reported to contribute to
increased breast cancer riskwomenwith exposure to cigarette
smoke [23, 24].
2.3. Mismatch Repair. During replication, base mismatches
can occur which distort the helical DNA structure [25].
These distortions are recognised by DNA damage response
machinery which initiates the excision of the mismatched
DNA, and the damaged site is then replaced with newly
synthesised DNA [25]. Defects in mismatch repair (MMR)
machinery are rarely seen in breast cancer, affecting 0.8–1.7%
of women with breast cancer [26, 27] whereas MMR defects
are seen in 15% of sporadic colorectal cancers [28]. There is
now a known association between mismatch repair mutation
andmicrosatellite instabilitywith response to immune check-
point therapies such as anti-PD-1; therefore identifying these
women may be of clinical importance [29].
2.4. Nonhomologous End Joining. The repair mechanism
nonhomologous end joining (NHEJ) is a simpler pathway
which functions throughout the cell cycle to repairDSBs [30].
Repair is mediated by ligating the ends of the broken DNA
strands together and therefore is prone to high rates of DNA
deletion and mutation [17]. Two distinct NHEJ pathways
are identified: classical and alternative NHEJ. Alternative
NHEJ is a less-well-defined process which has been shown
to have a higher probability of causing translocations and
large deletions [31]. When faithful repair, via homologous
recombination, is lost by mutation or epigenetic alterations
to this pathway, repair of double-strand breaks is performed
by NHEJ [32].
2.5. Homologous Recombination. Homologous recombina-
tion (HR) is one of the repair pathways responsible for the
detection and repair of double-strand breaks (DSBs) [33, 34].
This mechanism of repair is often described as conservative
as the original DNA sequence is restored at the damaged
lesion [35]. The process of HR is largely restricted to the S
and G2 phase of the cell cycle [36]. Nucleotides are excised
both upstream and downstream of the damaged site and new
DNA is synthesised using the homologous sister chromatid
as a template [37]. HR defects occur in between 25 and 40%
of breast cancers, from both germline and somatic mutations
of key components of theHRpathway such asBRCA1/BRCA2
[4, 6].
2.6. Fanconi Anemia/BRCA Pathway Loss. The Fanconi Ane-
mia (FA)/BRCA pathway is a complex mechanism that
involves the function of 19 genes and reestablishes DNA
replication following DNA damage through the coordination
of NER, translesional synthesis, and HR [38]. The FA/BRCA
pathway is lost in approximately 25% of breast cancers due to
mutation or silencing of one of constituent genes [4].
BRCA1 was the first identified breast cancer suscepti-
bility gene [39, 40] and is currently the newest member
of the FA family. Biallelic mutations in BRCA1 (typically
embryonically lethal) were identified in a patient with early
onset ovarian cancer with hypersensitivity to platinum based
treatment and therefore deemed a new subtype of Fanconi
Anemia (FANCS) [41]. BRCA2 (FANCD1) was identified
as a FA family member in 2002, following sequencing of
BRCA1 and BRCA2 in cells from patients with FANCB and
FANCD1 [42]. Mutations in other FA family members have
been demonstrated to predispose to breast cancer, including
PALB2 (FANCN), BRIP1 (FANCJ), RAD51C (FANCO), SLX4
(FANCP), andFANCM [43–50]. In summary, of the identified
genes predisposing to hereditary breast cancer, the majority
are FA family members.
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Table 1: DNA repair pathways mutated in breast cancer and potential therapeutic interventions.
DNA Repair
Pathway
Defective mutation in Breast
Cancer Therapeutic Intervention
Homologous
recombination
BRCA1, BRCA2, ATM, ATR,
CHK1, CHK2, BARD1, RAD51D,
NBS1, PALB2, FANCD2, CtIP,
PALB2 [17, 51–54]
Platinum based chemotherapies
[55], PARP inhibitors (immune
checkpoint blockade)
Non-homologous
end-joining DNA-PK, KU70/80 [56]
DNAPK inhibitors, ionizing
radiation
Mismatch repair MLH1, MSH2, MSH6, PMS2[57, 58] Immune checkpoint blockade
Base excision
repair, Nucleotide
excision repair,
Translesional
synthesis
APE1, XRCC1, ERCC2 [59, 60] APE1 inhibitors [61]
2.7. Somatic Mutations of DNA Repair Genes in Breast Cancer.
While BRCA1 and BRCA2 are highly penetrant germline
cancer predisposition genes, associated with familial breast
cancers, somatic alterations also affect these genes [78–81].
Somatic mutations of the FA pathway also occur frequently
in cancer and have been reported in 11.2% of breast can-
cers [82]. Promoter hypermethylation of BRCA1 has been
reported in 13%of sporadic breast tumors [83], with promoter
hypermethylation of FANCC (PALB2), FANCO (RAD51C),
and FANCF also reported [84–86]. Collectively, somatic and
germline mutations and alternations of BRCA and related
HR genes result in a phenotype termed “BRCAness” [87].
However, there may be significant clinical variation in how
germline vs somatic mutations and alterations behave in
response to therapy, exemplified by improved response to
carboplatin vs docetaxel observed in patients with germline
BRCA1 mutations but not in those with BRCA1 methylation
or lowmRNAexpression [55]. However, while novelmethods
may allow variants of unknown significance and novel muta-
tions of unknown pathogenic impact to be more clearly clas-
sified [88], taking this phenotypic approach to classification
of BRCA-mutant-like HR-deficient cancers allows for clinical
trial design targeting this subgroup of breast cancer.
2.8. Transcriptomic Identification of DNA Repair Deficiency.
Tumors with loss of the FA/BRCA DNA repair pathway
are sensitive to DNA damaging agents that cross-link DNA
and stall DNA replication such as alkylating agents and
anthracyclines. We previously identified a gene expression
signature assay capable of prospectively identifying this dis-
tinct molecular subgroup of breast cancer patients with loss
of the FA/BRCA pathway who benefited from chemotherapy
[89]. Importantly, characterisation of the genes activated
by loss of the FA/BRCA pathway revealed interferon-type
immune gene signalling [90].
Consistent with this observation, both BRCA1 and
BRCA2 mutant breast cancers are known to be associated
with lymphocytic infiltration [91, 92]. Cell line modelling
demonstrates that loss of BRCA1/2 results in upregula-
tion of interferon related genes [93, 94]. Importantly the
CXCL10/CXCR3 axis is activated in BRCA-mutant breast
cancer and has been implicated in breast cancer progression
and metastasis in both in vivo and clinical studies [95, 96].
3. Immune Response in Breast Cancer
A number of clinical trials have reported a favourable predic-
tive and prognostic value of tumor infiltrating lymphocytes
(TILs) in different pathological subtypes of breast cancer
[9, 97, 98]. Lymphocytic infiltration is particularly recognised
in tumors associated with genomic instability, such as those
with a BRCA1 mutation [4, 91]. Increasing presence of TILs
has been correlated with improved recurrence free survival
following chemotherapeutic treatment of triple negative and
HER2+ breast cancers [99]. In TNBC, a phase III clinical trial
reported that each consecutive 10% increase in intratumoral
and stromal TILs resulted in 15% reduced risk of recurrence
and 17% reduced risk of cancer related death, irrespective
of the type of chemotherapy administered [100]. However,
in the same study increased TILs were predictive of poorer
outcome in ERpositiveHER2negative breast cancer. Notably,
high FoxP3+ T-regulatory cells (Tregs) have been associated
with poorer outcomes in ER positive disease, yet improved
outcomes in ER negative breast cancer [101, 102]. Examining
lymphocytic infiltration as a whole may overlook the subtle
effects of the different populations of lymphocytes present in
the tumor and stroma.
Whereas BRCA1/2 mutant breast tumors have been
recognised to be associated with increased lymphocytic infil-
trate [87], early data suggests that loss of other DNA repair
response proteins (for example, ATM) results in a markedly
altered immune response and tumor microenvironment,
with low levels of tumor infiltrating lymphocytes [103]. The
evolution of the term “BRCAness” to describe a BRCA-
mutant phenotype in tumors without BRCA1/2 mutations
has enabled classification of this important subgroup of
breast cancer but may overlook subtle differences in immune
responses that may vary depending on specific “BRCAness”
associated alterations. For example, although it is known that
loss of heterozygosity may have a greater influence on tumor
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behavior than biallelic alterations resulting from two somatic
events [88], the exact impact biallelic vs monoallelic alter-
ations of HR-related genes may have on immune activation
and response to immune blockade is unknown.
Despite the T-cell immune infiltration commonly present
in BRCA-mutant and DNA damage response deficient
breast cancers, tumor growth and invasion continue. There-
fore DNA repair deficient tumors develop mechanisms of
bypassing the antitumorigenic immune response, thriving
in an inflamed microenvironment. The chronic inflamma-
tion mediated by DNA repair deficiency within the tumor
microenvironment promotes cellular proliferation and inva-
sion and, in addition, dysregulated pathways of immune
equilibrium, thereby promoting immunosuppression [104–
106].
3.1. STING Activation in DNA Damage Response Deficiency.
Defects inDNA repair genes including BRCA1 andATM have
been shown to result in constitutive activation of the STim-
ulator of INterferon Genes (STING) pathway in response to
accumulation of cytosolic DNA [90, 107, 108]. Failed DNA
repair results in the formation of micronuclei, within which
cyclic GMP-AMP synthase (cGAS) colocalises with damaged
DNA [109, 110]. Ruptured micronuclei result in activation
of cGAS with subsequent synthesis of 2’3’-cGAMP which
potently activates the STING pathway [111, 112]. Downstream
activation of TANK-binding kinase 1 (TBK1) and interferon
regulatory factor 3 (IRF3) then occurs, as well as canonical
and noncanonical NF𝜅B pathways, resulting in upregulation
of interferon stimulated genes [113, 114]. Interestingly, as well
as activation of the STING pathway in DNA repair deficient
cells, DNA damaging chemotherapies (including irinotecan,
doxorubicin, and etoposide) and radiotherapy have similarly
been demonstrated to activate the cGAS-STING immune
response pathway [115–117].
STING agonists are now in early phase clinical trials in
combination with immune checkpoint therapies based on
their ability to induce immune responses in solid tumors
[118, 119]. Activation of the cytosolic RNA-sensing RIG-I
pathway has also been identified in breast cancer treated with
doxorubicin [120], and similarly to STING agonists, RIG-I
agonists are also in clinical development, with immunostim-
ulatory effects on the tumor microenvironment and tumor
clearance in murine models [121].
STING agonists cause upregulation of immune check-
points including PD-L1 in the microenvironment [122], and
upregulation of PD-L1 in response to DNA damage has been
shown to be dependent on STING [90, 123]. PD-L1 expressing
tumors (with PD-L1 identified on infiltrating immune cells ±
epithelial cells) aremore likely to respond to targeted immune
therapies.
However, STING activation following radiotherapy has
been shown to drive infiltration of immunosuppressive
myeloid derived suppressor cells (MDSCs) [124]. In breast
cancer, infiltration of MDSCs has been reported to pro-
mote progression and metastasis and may mediate resistance
to immunotherapies [125]. Whether infiltration of these
immunosuppressive cells is mediated by STING activation
in breast cancer remains unclear. STING pathway activa-
tion may therefore have dichotomous effects on the tumor
microenvironment. While STING activation in the acute
phase is typically recognised to have an antitumorigenic
immunogenic effect, chronic cGAS-STING activation may
in fact result in an immunosuppressive microenvironment,
activating the senescence associated secretory phenotype
[126–128] and upregulation of immune checkpoints [90].
Moreover, chronic activation of cGAS-STING in chromoso-
mally unstable tumors has been shown to result in STING-
dependent metastasis [129]. The potential role of the STING
pathway in the tumor immune microenvironment is illus-
trated in Figure 1.
3.2. Immune Checkpoints in Breast Cancer. Immune check-
points are a number of inhibitory pathways within the
immune system responsible for maintaining self-tolerance
and modulation of the immune response [130]. Studies have
reported that tumors are able to select particular immune
checkpoint pathways to evade the immune system, partic-
ularly T-cells which target tumor antigens. This results in
immune checkpoint proteins being frequently dysregulated
in cancer [131].
When an antigen is recognised by the T-cell receptor, an
immune response is initiated and then regulated by immune
checkpoints via inhibitory and costimulatory signals [132].
Costimulatory receptor agonists or antagonists of inhibitory
signals augment antigen-specific T-cell responses [133].
Although other forms of immunotherapy are also used
in the clinical setting, the use of immune checkpoint tar-
geted therapies has undoubtedly been remarkably successful,
unleashing the potential of the antitumor immune response
and revolutionising themanagement of human cancers [134].
Targeting the PD-1/L1 axis has been most fruitful in clinical
trials, with many ongoing combination studies now using
PD-1/L1 as a backbone of therapy (Table 2).
3.3. PD-1 and Ligands PD-L1/PD-L2. PD-1 is a transmem-
brane inhibitory coreceptor. Expression of PD-1 on T-cells
and PD-L1 ligand interaction has been shown to have
immunosuppressive functions in the tumor microenviron-
ment [135]. PD-L2 expression is much more restricted than
PD-L1 and so is mainly found on the surface of Antigen
Presenting Cells (APCs) associated with its role in regulating
the priming of T-cells [136].
PD-L1 expression is reported to be upregulated across
a range of cancer types including breast, gastric, and lung
cancers, although the significance of PD-L1 on prognosis and
outcome remains uncertain in breast cancer [137, 138]. In the
tumor microenvironment, PD-1/PD-L1 interaction results
in T-cell death and inhibition of cytotoxic T-cell function
[139]. Additionally, immunosuppressive Interleukin-10 (IL-
10) production is stimulated [140]. Furthermore, PD-L1
expression enhances the conversion of helper T-cells (Th1)
into immunosuppressive Tregs [141, 142]. Inhibiting the PD-
1/PD-L1 pathway using PD-1 or PD-L1 targeting antibodies
restores lymphocyte function and therefore cytotoxicity [143].
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Table 2: Current and completed clinical trials of immune checkpoint inhibition in breast cancer.
Immunotherapy Subtype Target Combination Study Phase
Pembrolizumab TNBCER+/HER2- PD-1 Single agent
NCT02555657
KEYNOTE-119 [62] 3
Pembrolizumab BRCA mutated PD-1 Single Agent NCT03025035 2
Pembrolizumab TNBCER+/HER2- PD-1 Single agent
NCT02447003
KEYNOTE-086 [63] 2
Pembrolizumab TNBCER+/HER2- PD-1 Single agent
NCT01848834
KEYNOTE-012 [64] 1B
Pembrolizumab TNBCER+/HER2- PD-1 Single agent
NCT02054806
KEYNOTE-028 [65] 1
Pembrolizumab ER/PR- PD-1 Single Agent NCT03197389 1
Pembrolizumab
TNBC
and
HR+HER2-
PD-1 Decitabine + SocNACT NCT02957968 2
Pembrolizumab TNBC PD-1 EDP1503 NCT03775850 2
Pembrolizumab TNBC PD-1 Imprime PGG NCT02981303 2
Pembrolizumab HR+HER2- PD-1 Eribulin NCT03222856KELLY [66] 2
Pembrolizumab TNBC PD-1 Chemotherapy NCT01042379I-SPY 2 [64, 67] 2
Pembrolizumab TNBC PD-1 Galinpepimut-S NCT03761914 2
Pembrolizumab TNBC PD-1
Nab-paclitaxel +
Epirubicin +
Cyclophosphamide
NCT03289819 2
Pembrolizumab TNBC PD-1 Chemotherapy NCT02622074KEYNOTE-173 [68] 1B
Pembrolizumab ER+HER2- /TNBC PD-1
Radiation
Radiation NCT03366844 1
Pembrolizumab Metastatic BC PD-1 High IntensityUltrasound NCT03237572 1
Pembrolizumab All PD-1 Stereotactic AblativeRadiosurgery
NCT02303366
BOSTON II 1
Pembrolizumab TNBC PD-1 PVX-410 vaccine NCT03362060 1
PDR001 TNBC PD-1
Canakinumab
CJM112
Trametinib
EGF816
NCT02900664 1B
PDR001 TNBC PD-1
LCL161
Everolimus
Panobinostat
QBM076
NCT02890069 1
PDR001 TNBC PD-1 NZV930NZV930 + NIR178 NCT03549000 1
Durvalumab TNBC PD-L1
Single agent
Taxane-anthracycline
chemotherapy
NCT02685059
GeparNuevo [69] 2
Durvalumab +/-
Tremelimumab All
PD-L1 +/-
CTLA-4 Poly ICLC NCT02643303 2
Durvalumab BRCA mutatedHER2- PD-L1
Olaparib
+Bevacizumab
NCT02734004
MEDIOLA [70] 2
Durvalumab TNBC PD-L1 Paclitaxel andCarboplatin
NCT03616886
SYNERGY 2
Durvalumab BRCA mutatedHER2- PD-L1 Olaparib
NCT02734004
MEDIOLA [70] 1
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Table 2: Continued.
Immunotherapy Subtype Target Combination Study Phase
Durvalumab TNBC PD-L1
Paclitaxel,
Carboplatin and
Oleclumab
NCT03616886
SYNERGY 1
Durvalumab TNBC PD-L1
Cediranib
Olaparib
Cediranib + Olaparib
NCT02484404 1
Atezolizumab TNBC PD-L1 Single agent NCT01375842 [71] 1
Atezolizumab TNBC PD-L1 Nab-paclitaxel NCT02425891IMpassion130 [14] 3
Atezolizumab HER2+ PD-L1 TrastuzumabEmtansine
NCT02924883
KATE2 [72] 2
Atezolizumab TNBC PD-L1 Cabozantinib NCT03170960 1B
Atezolizumab TNBC PD-L1 RO7198457 NCT03289962 1
Nivolumab TNBC PD-L1 Romidepsin +Cisplatin NCT02393794 2
Nivolumab TNBC PD-L1 Capecitabine NCT03487666OXEL [73] 2
Nivolumab Metastatic PD-L1 Nab-paclitaxel NCT02309177 1
Nivolumab All PD-L1 COM701 NCT03667716 1
Avelumab TNBC PD-L1 Additional NCT02926196A-Brave [74] 3
Avelumab TNBC PD-L1 Utomilumab NCT02554812JAVELIN [75] 2
Avelumab All PD-L1
Utomilumab +/-
Radiation
Utomilumab +
PF-04518600
PF-04518600 +/-
Radiation
Utomilumab +
PF-04518600 +
Radiation
Cisplatin + Radiation
NCT03217747 2
FAZ053 TNBC PD-L1 Single AgentPDR001 NCT02936102 1
LY3300054 HR+HER2- PD-L1
Single Agent
Ramucirumab
Abemaciclib
Merestinib
LY3321367
NCT02791334 1
Tremelimumab TNBC CTLA-4 Monotherapy NCT02527434 [76] 2
MSB0011359C ER+ and/orPR+, HER2-
PD-L1 and
TGF-𝛽 Radiation
NCT03524170
RACHEL 1 1
LAG525 TNBC LAG3
Single agent
PDR001 / Carboplatin
or combination
NCT03499899 2
Toripalimab TNBC PD-1 Single Agent NCT02838823 1
TT1-621 All CD47
Single Agent
+PD1/PDL1 inhibitor
+Pegylated
interferon- 𝛼2a
+T-Vec
+Radiation
NCT02890368 1
Ipilimumab +
Nivolumab HER2-
CTLA-4
PD-1 Bicalutamide NCT03650894 2
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Table 2: Continued.
Immunotherapy Subtype Target Combination Study Phase
Ipilimumab +
Nivolumab HER2-
CTLA-4
PD-1
NCT03789110
NIMBUS 2
Epacadostat +
Pembrolizumab All
IDO-1
PD-1
INCAGN01876
(anti-GITR) NCT03277352 1/2
Ipilimumab +
Nivolumab All
PD-1
PD-L1 Entinostat NCT02453620 1
Nivolumab +
Pembrolizumab +
Atezolizumab
HER2+
PD-L1
PD-1
PD-L1
FT500 (Natural Killer
cell) NCT03841110 1
Ipilimumab +
Nivolumab All
CTLA-4 +
PD-L1 Cryoablation NCT02833233 [77] N/A
FA/BRCA deﬁcient cancer cell CTLA4
PD-L1
FoxP3+, TAMs, CD4+ and CD8+ also express 
TIM3 and LAG3 
CTLA4
PD-1
PD-1
PD-L1
CD80
CD86
PD-1
Interferons and chemokines
CD8+ and CD4+ TILs
cGAMP
STING
Stalled DNA 
replication
Figure 1: STING pathway activation in DNA repair deficient breast cancer. Stalled replication forks or damaged DNA as a result of mutations
in Fanconi Anemia/BRCA repair pathway genes results in cytosolic DNA, detected by cGAS. 2’3’-cGAMP is produced, which then activates
STING. STING dimerises or oligomerises, and TBK1 and IRF3 are phosphorylated. IRF3 then translocates to the nucleus resulting in the
expression of immune genes including CXCL10 and CCL5. Note: other downstream activators of the STING pathway, notably TRAF6 and
NF𝜅B, are not shown in this instance. CXCL10 and CCL5 are implicated in chemoattraction of CD8+ and CD4+ T-cells. However the tumor
microenvironment may also contain immunosuppressive FoxP3+ CD4+ cells which express CTLA4, PD-1, PD-L1, LAG3, and TIM3; tumor-
associated macrophages (TAMs) which express PD-1, PD-L1, CD80 and CD86, LAG3, and TIM3. Tumor infiltrating lymphocytes (TILs) may
express CTLA4, PD-1, TIM3, and LAG3.Therefore, DNA repair deficiency results in activation of the cGAS-STING pathway which has both
antitumorigenic and protumorigenic effects within the tumor microenvironment.
PD-L1 has been reported to be expressed epithelial cells
in 20% of triple negative breast cancers [13] and has been
proposed as a biomarker of response to immunotherapy.
However the failure to respond in PD-L1 positive breast
tumors (in up to 75% depending on the treatment setting)
and the observed response in some PD-L1 low or negative
tumors indicate that other markers of response need to be
identified [134, 144]. The most promising of these in solid
tumors has been the presence of microsatellite instability,
leading to approval of immune checkpoint therapy in all
advanced solid tumors with mismatch repair defects [145].
However, as discussed above, the incidence of these defects
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in breast cancer is low. Similarly tumor mutational burden
(TMB) is a promising biomarker in other solid tumors, but
most breast cancers do not typically demonstrate increased
TMB [146].
Increased PD-L1 expression is identified in breast tumors
deficient in DNA repair, and infiltrating immune-cell PD-1
and PD-L1 expression is higher in breast cancers with BRCA1
or BRCA2 mutations [90, 147]. Treatment with the DNA
damaging agent doxorubicin results in increased expression
of PD-L1 on breast cancer cells [148]. Interestingly, STING
agonists given in combination with anti-PD-1 treatment
result in improved responses in preclinical models [122].
Therefore, a close relationship is observed between DNA
repair deficiency and upregulation of PD-L1 expression.
Breast cancers with DNA repair deficiency, or BRCAness,
may benefit from single agent immunotherapy targeting
this pathway. However, independent of BRCAness, treatment
of breast cancers with DNA damaging agents in combina-
tion with anti-PD-1/PD-L1 targeted therapy may result in
enhanced tumor responses.
4. Immunotherapy in Breast Cancer
In metastatic TNBC, the combination of PD-L1 targeting
atezolizumab with nab-paclitaxel resulted in a median 9.5-
month improvement in overall survival (HR 0.62, 95% CI
0.45–0.86) in patients with PD-L1 positive immune infiltra-
tion [14]. In early stage breast cancer, neoadjuvant treatment
of TNBC with anti-PD-1 in combination with chemotherapy
resulted in an increase in pathological complete response
(pCR) rates of 40% above expected [15]. These promising
results indicate the potential of immunotherapy in breast
cancer, although single agent anti-PD-1 treatment in the
metastatic setting has not demonstrated a similar magni-
tude, with response rates of less than 20% in unselected
advanced triple negative breast cancer, supporting combina-
tion approaches in future clinical trials [149].
Over 50 immune checkpoint therapy single agent and
combination trials are ongoing in breast cancer, summarised
in Table 2. The rate of translating these promising preclinical
findings into the clinic is highly commendable and offers
many patients a much-needed treatment option. However,
the lack of an effective biomarker to select patients for
immune checkpoint therapy exposes many patients who
may derive no benefit from treatment to the risk of poten-
tially serious immune mediated side effects, such as colitis,
pneumonitis, liver toxicity, and durable endocrine effects
including hypophysitis [150].
4.1. PARP Inhibitor and Immunotherapy Combinations
in Breast Cancer. Poly(ADP-ribose) polymerase (PARP)
inhibitors (inhibiting PARP1, involved in base excision
repair) initially demonstrated efficacy in potentiating the
effects of DNA damagers such as temozolomide [151].
Subsequently treatment with PARP inhibitors was found
to result in synthetic lethality in BRCA1/2 mutant tumors
[152, 153] and the PARP inhibitors olaparib and talazoparib
are now FDA-approved as monotherapy treatments in
BRCA1/2 mutant advanced breast cancer [154, 155].
As discussed above, the immune microenvironment of
DNA repair deficient tumors is typically immunosuppressive
with an exhausted T-cell infiltrate expressing high levels of
checkpoints. However, as described by Yap and colleagues,
the targeted cell death caused by PARP inhibitors has
the potential to “reset” the tumor microenvironment and
polarise the immune response towards a Th1 antitumorigenic
profile, resulting in a shift from immune escape to elimination
of the tumor [156]. Therefore PARP inhibitors represent a
promising combination therapy with immune checkpoint
targeting therapies.
PARP inhibitors have now been demonstrated in a num-
ber of preclinical studies to activate the innate immune cGAS-
STING pathway [157–160]. These studies have further eluci-
dated the mechanism of action of PARP inhibitors beyond
synthetic lethality. Strikingly, treatment in vivowith the PARP
inhibitor talazoparib in immunocompromised compared to
immunocompetent models results in diminished responses
[157]. Moreover, STING-dependent infiltration of CD8+ T-
cells was demonstrated to be required for response to the
PARP inhibitor olaparib [160].These preclinical studies build
a strong case for PARP inhibitor–immune checkpoint com-
bination studies and the crucial role of the STING pathway
in mediating immune responses. Interestingly these studies
demonstrate a PARP inhibitor driven immune response in
bothHR-deficient and -proficient models [157, 160], support-
ing the rationale for PARP-immune checkpoint combinations
beyond BRCA-mutant or HR-deficient disease.
In breast cancer, the combination of olaparib and dur-
valumab resulted in an overall response rate of 63% (95%
CI 44–80%) at 28 weeks in 30 patients with germline
BRCA1/2 mutations [161]. These promising results have led
to the expansion of this study beyond germline BRCA-
mutant disease to encompass homologous recombination
deficient cancers [70]. In advanced TNBC the combination of
niraparib and pembrolizumab demonstrated clinical benefit
in 20 out of 46 patients, notably including 4 patients with
no identified HR defect or detectable PD-L1 expression [162].
While it is likely that the dual combination of PARP inhibition
and immune checkpoint blockade results in most marked
responses in DNA repair deficient cancers, the addition of
a third immune-stimulating or targeted agent may enhance
responses in repair competent tumors. For example, the
addition of antiangiogenic therapy may further stimulate an
antitumorigenic immune response by inhibiting immuno-
suppressive effects of VEGF-A, which promotes infiltration
of MDSCs and Tregs and prevents dendritic cell maturation
[163]. A number of triplet combination studies, including
PARPi, antiangiogenic and immune checkpoint blockade, are
ongoing (Table 2).
5. Conclusions
It is clear that the immune system plays a significant role
in tumor development, progression, and also response to
therapy. Immune checkpoints are implicated in the process
of immunosuppression and therefore represent ideal targets
for therapeutic manipulation to encourage an antitumor
Journal of Oncology 9
immune response. As outlined here and elsewhere, there is a
strong argument for the immune response to genomic insta-
bility as an independent biomarker in identifying candidates
for immune targeting treatments [164].
DNA repair deficient breast cancer, identified using
genomic or transcriptomic biomarkers of DNA repair, is
associated with upregulation of immune checkpoints and an
immune-cell infiltrated microenvironment. While activation
of immune pathways such as STING in the acute phase
promotes an antitumorigenic response, in the chronic phase
DNA damage repair deficient tumors instead exploit this
STING-mediated immune response, tailoring this to promote
a proinvasive microenvironment favouring tumor growth.
Moreover, this immune microenvironment can be further
hijacked by chronic stimulation of pathways such as the
senescence associated secretory phenotype, again favouring
immunosuppression and immune escape [165].
As the immune microenvironment of chronically
inflamed DNA repair deficient cancer consists of both anti-
tumorigenic and immunosuppressive cell populations, thera-
pies which therefore enhance the antitumor immune infiltra-
tion and activation, in combination with immune checkpoint
therapies, represent a promising treatment strategy.
Conflicts of Interest
Richard D. Kennedy and Nuala McCabe are employees of
Almac Diagnostics.
Authors’ Contributions
Eileen E. Parkes, Richard D. Kennedy, and Nuala McCabe
were responsible for conceptualization; Elaine Gilmore,
Nuala McCabe, Richard D. Kennedy, and Eileen E. Parkes
wrote and prepared the original draft; Eileen E. Parkes,
Richard D. Kennedy, Nuala McCabe, and Elaine Gilmore
wrote, reviewed, and edited the manuscript; Eileen E. Parkes
and Richard D. Kennedy were responsible for visualization;
Eileen E. Parkes, Richard D. Kennedy, and Nuala McCabe
supervised the work.
Acknowledgments
Eileen E. Parkes is supported by the Academy of Medical
Sciences, the Conquer Cancer Foundation of the American
Society of Clinical Oncology, and the Prostate Cancer Foun-
dation.
References
[1] S. P. Jackson and J. Bartek, “The DNA-damage response in
human biology and disease,”Nature, vol. 461, no. 7267, pp. 1071–
1078, 2009.
[2] S. Negrini, V. G. Gorgoulis, and T. D. Halazonetis, “Genomic
instability—an evolving hallmark of cancer,” Nature Reviews
Molecular Cell Biology, vol. 11, no. 3, pp. 220–228, 2010.
[3] A. Tubbs and A. Nussenzweig, “Endogenous DNA damage as a
source of genomic instability in cancer,” Cell, vol. 168, no. 4, pp.
644–656, 2017.
[4] N. Turner, A. Tutt, and A. Ashworth, “Hallmarks of
“BRCAness” in sporadic cancers,” Nature Reviews Cancer,
vol. 4, no. 10, pp. 814–819, 2004.
[5] E.H. Lips, L.Mulder, J. Hannemann et al., “Indicators of homol-
ogous recombination deficiency in breast cancer and associ-
ation with response to neoadjuvant chemotherapy,” Annals of
Oncology, vol. 22, no. 4, pp. 870–876, 2011.
[6] S. Akashi-Tanaka, C. Watanabe, T. Takamaru et al., “BRCAness
predicts resistance to taxane-containing regimens in triple neg-
ative breast cancer during neoadjuvant chemotherapy,” Clinical
Breast Cancer, vol. 15, no. 1, pp. 80–85, 2015.
[7] D. Hanahan and R. A.Weinberg, “Hallmarks of cancer: the next
generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[8] R. M. Bremnes, L. Busund, T. L. Kilvær et al., “The role of
tumor-infiltrating lymphocytes in development, progression,
and prognosis of non–small cell lung cancer,” Journal ofThoracic
Oncology, vol. 11, no. 6, pp. 789–800, 2016.
[9] S. J. Luen, R. Salgado, S. Fox et al., “Tumor-infiltrating lym-
phocytes in advanced HER2-positive breast cancer treated
with pertuzumab or placebo in addition to trastuzumab and
docetaxel: a retrospective analysis of the CLEOPATRA study,”
The Lancet Oncology, vol. 18, no. 1, pp. 52–62, 2017.
[10] J. R.Webb, K.Milne, P.Watson, R. J. deLeeuw, and B. H. Nelson,
“Tumor-infiltrating lymphocytes expressing the tissue resident
memory marker CD103 are associated with increased survival
in high-grade serous ovarian cancer,” Clinical Cancer Research,
vol. 20, no. 2, pp. 434–444, 2014.
[11] M. J. Ward, S. M. Thirdborough, T. Mellows et al., “Tumour-
infiltrating lymphocytes predict for outcome in HPV-positive
oropharyngeal cancer,” British Journal of Cancer, vol. 110, no. 2,
pp. 489–500, 2014.
[12] S. Loi, S. Michiels, R. Salgado et al., “Tumor infiltrating
lymphocytes are prognostic in triple negative breast cancer and
predictive for trastuzumab benefit in early breast cancer: results
from the FinHER trial,” Annals of Oncology, vol. 25, no. 8, pp.
1544–1550, 2014.
[13] E. A. Mittendorf, A. V. Philips, F. Meric-Bernstam et al., “PD-L1
expression in triple-negative breast cancer,”Cancer Immunology
Research, vol. 2, no. 4, pp. 361–370, 2014.
[14] P. Schmid, S. Adams, H. S. Rugo et al., “Atezolizumab and nab-
paclitaxel in advanced triple-negative breast cancer,” The New
England Journal ofMedicine, vol. 379, no. 22, pp. 2108–2121, 2018.
[15] R. Nanda, M. C. Liu, C. Yau et al., “Pembrolizumab plus
standard neoadjuvant therapy for high-risk breast cancer (BC):
Results from I-SPY 2,” Journal of Clinical Oncology, vol. 35,
article no 506, Supplement 15, 2017.
[16] S. Loi, A. Giobbie-Hurder, A. Gombos et al., “Pembrolizumab
plus trastuzumab in trastuzumab-resistant, advanced, HER2-
positive breast cancer (PANACEA): a single-arm, multicentre,
phase 1b–2 trial,” The Lancet Oncology, vol. 20, no. 3, pp. 371–
382, 2019.
[17] C. J. Lord and A. Ashworth, “The DNA damage response and
cancer therapy,” Nature, vol. 481, no. 7381, pp. 287–294, 2012.
[18] M. J. O’Connor, “Targeting the DNA damage response in
cancer,”Molecular Cell, vol. 60, no. 4, pp. 547–560, 2015.
[19] M. L. Hegde, T. K. Hazra, and S. Mitra, “Early steps in the
DNA base excision/single-strand interruption repair pathway
inmammalian cells,”Cell Research, vol. 18, no. 1, pp. 27–47, 2008.
[20] M. Cuchra, B. Mucha, L. Markiewicz et al., “The role of base
excision repair in pathogenesis of breast cancer in the Polish
population,”Molecular Carcinogenesis, vol. 55, no. 12, pp. 1899–
1914, 2016.
10 Journal of Oncology
[21] C. Patrono, “Polymorphisms in base excision repair genes:
Breast cancer risk and individual radiosensitivity,” World Jour-
nal of Clinical Oncology, vol. 5, no. 5, pp. 874–882, 2014.
[22] E. C. Friedberg, “How nucleotide excision repair protects
against cancer,” Nature Reviews Cancer, vol. 1, no. 1, pp. 22–33,
2001.
[23] J. J. Latimer, J. M. Johnson, C. M. Kelly et al., “Nucleotide
excision repair deficiency is intrinsic in sporadic stage i breast
cancer,” Proceedings of the National Acadamy of Sciences of the
United States of America, vol. 107, no. 50, pp. 21725–21730, 2010.
[24] L. E. Mechanic, R. C. Millikan, J. Player et al., “Polymor-
phisms in nucleotide excision repair genes, smoking and breast
cancer in African Americans and whites: a population-based
case–control study,” Carcinogenesis, vol. 27, no. 7, pp. 1377–1385,
2006.
[25] G.M. Li, “Mechanisms and functions of DNAmismatch repair,”
Cell Research, vol. 18, no. 1, pp. 85–98, 2008.
[26] H. Davies, S. Morganella, C. A. Purdie et al., “Whole-genome
sequencing reveals breast cancers with mismatch repair defi-
ciency,” Cancer Research, vol. 77, no. 18, pp. 4755–4762, 2017.
[27] M. E. Roberts, S. A. Jackson, L. R. Susswein et al., “MSH6 and
PMS2 germ-line pathogenic variants implicated in Lynch syn-
drome are associated with breast cancer,” Genetics in Medicine,
vol. 20, no. 10, pp. 1167–1174, 2018.
[28] J. M. D. Wheeler, W. F. Bodmer, and N. J. McC Mortensen,
“DNA mismatch repair genes and colorectal cancer,” Gut, vol.
47, no. 1, pp. 148–153, 2000.
[29] D. T. Le, J. N. Uram, H. Wang et al., “PD-1 blockade in tumors
with mismatch-repair deficiency,” The New England Journal of
Medicine, vol. 372, no. 26, pp. 2509–2520, 2015.
[30] A. J. Davis and D. J. Chen, “DNA double strand break repair via
non-homologous end-joining,” Transl Cancer Res, vol. 2, no. 3,
pp. 130–143, 2013.
[31] M. Gostissa, F. W. Alt, and R. Chiarle, “Mechanisms that
promote and suppress chromosomal translocations in lympho-
cytes,”Annual Review of Immunology, vol. 29, no. 1, pp. 319–350,
2011.
[32] M. R. Lieber, “The mechanism of double-strand DNA break
repair by the nonhomologous DNA end-joining pathway,”
Annual Review of Biochemistry, vol. 79, pp. 181–211, 2010.
[33] R. G. Sargent, M. A. Brenneman, and J. H. Wilson, “Repair
of site-specific double-strand breaks in a mammalian chromo-
some by homologous and illegitimate recombination.,”Molecu-
lar and Cellular Biology, vol. 17, no. 1, pp. 267–277, 1997.
[34] C. Arnaudeau, C. Lundin, andT.Helleday, “DNAdouble-strand
breaks associated with replication forks are predominantly
repaired by homologous recombination involving an exchange
mechanism in mammalian cells,” Journal of Molecular Biology,
vol. 307, no. 5, pp. 1235–1245, 2001.
[35] W. D. Wright, S. S. Shah, and W.-D. Heyer, “Homologous
recombination and the repair of DNA double-strand breaks,”
The Journal of Biological Chemistry, vol. 293, no. 27, pp. 10524–
10535, 2018.
[36] X. Zhao, C. Wei, J. Li et al., “Cell cycle-dependent control
of homologous recombination,” Acta Biochimica et Biophysica
Sinica, vol. 49, no. 8, pp. 655–668, 2017.
[37] M. E. Moynahan, T. Y. Cui, and M. Jasin, “Homology-directed
DNA repair, mitomycin-C resistance, and chromosome stabil-
ity is restored with correction of a Brca1 mutation,” Cancer
Research, vol. 61, no. 12, pp. 4842–4850, 2001.
[38] R. D. Kennedy andA. D. D’Andrea, “The fanconi anemia/BRCA
pathway: new faces in the crowd,”Genes &Development, vol. 19,
no. 24, pp. 2925–2940, 2005.
[39] J. M. Hall, M. K. Lee, B. Newman et al., “Linkage of early-onset
familial breast cancer to chromosome 17q21,” Science, vol. 250,
no. 4988, pp. 1684–1689, 1990.
[40] Y. Miki, J. Swensen, D. Shattuck-Eidens et al., “A strong
candidate for the breast and ovarian cancer susceptibility gene
BRCA1,” Science, vol. 266, no. 5182, pp. 66–71, 1994.
[41] S. L. Sawyer, L. Tian, M. Ka¨hko¨nen et al., “Biallelic mutations in
BRCA1 cause a newFanconi anemia subtype,”CancerDiscovery,
vol. 5, no. 2, pp. 135–142, 2015.
[42] N. G. Howlett, T. Taniguchi, S. Olson et al., “Biallelic inactiva-
tion of BRCA2 in Fanconi anemia,” Science, vol. 297, no. 5581,
pp. 606–609, 2002.
[43] M. Tischkowitz and B. Xia, “PALB2/FANCN: Recombining
cancer and fanconi anemia,” Cancer Research, vol. 70, no. 19, pp.
7353–7359, 2010.
[44] A. C. Antoniou, S. Casadei, T. Heikkinen et al., “Breast-cancer
risk in families with mutations in PALB2,” The New England
Journal of Medicine, vol. 371, no. 6, pp. 497–506, 2014.
[45] C. Cybulski, W. Kluz´niak, T. Huzarski et al., “Clinical outcomes
in women with breast cancer and a PALB2mutation: a prospec-
tive cohort analysis,”TheLancetOncology, vol. 16, no. 6, pp. 638–
644, 2015.
[46] M. Levitus, Q.Waisfisz, B. C. Godthelp et al., “TheDNAhelicase
BRIP1 is defective in Fanconi anemia complementation group
J,” Nature Genetics, vol. 37, no. 9, pp. 934-935, 2005.
[47] O. Levran, C. Attwooll, R. T. Henry et al., “The BRCA1-
interacting helicase BRIP1 is deficient in Fanconi anemia,”
Nature Genetics, vol. 37, no. 9, pp. 931–933, 2005.
[48] Y. Kim, G. S. Spitz, U. Veturi, F. P. Lach, A. D. Auerbach, and A.
Smogorzewska, “Regulation of multiple DNA repair pathways
by the Fanconi anemia protein SLX4,” Blood, vol. 121, no. 1, pp.
54–63, 2013.
[49] S. Shah, Y. Kim, I. Ostrovnaya et al., “Assessment of SLX4
mutations in hereditary breast cancers,” PLoS ONE, vol. 8, no.
6, Article ID e66961, 2013.
[50] J. I. Kiiski, L. M. Pelttari, S. Khan et al., “Exome sequencing
identifies FANCM as a susceptibility gene for triple-negative
breast cancer,” Proceedings of the National Acadamy of Sciences
of the United States of America, vol. 111, no. 42, pp. 15172–15177,
2014.
[51] J. S. Brown, B. O’Carrigan, S. P. Jackson, and T. A. Yap,
“Targeting DNA repair in cancer: beyond PARP inhibitors,”
Cancer Discovery, vol. 7, no. 1, pp. 20–37, 2017.
[52] T. Aparicio and J. Gautier, “BRCA1-CtIP interaction in the
repair of DNA double-strand breaks,” Molecular & Cellular
Oncology, vol. 3, no. 4, Article ID e1169343, 2016.
[53] K. J. Patel, “Fanconi anemia and breast cancer susceptibility,”
Nature Genetics, vol. 39, no. 2, pp. 142-143, 2007.
[54] R. Roy, J. Chun, and S.N. Powell, “BRCA1 andBRCA2:Different
roles in a common pathway of genome protection,” Nature
Reviews Cancer, vol. 12, no. 1, pp. 68–78, 2012.
[55] A. Tutt, H. Tovey, M. C. Cheang et al., “Carboplatin in
BRCA1/2-mutated and triple-negative breast cancer BRCAness
subgroups: the TNT Trial,” Nature Medicine, vol. 24, no. 5, pp.
628–637, 2018.
[56] B. J. Sishc andA. J. Davis, “The role of the core non-homologous
end joining factors in carcinogenesis and cancer,” Cancers
(Basel), vol. 9, no. 7, 2017.
Journal of Oncology 11
[57] H. Murata, N. H. Khattar, L. Gu, and G. Li, “Roles of mismatch
repair proteins hMSH2 and hMLH1 in the development of
sporadic breast cancer,” Cancer Letters, vol. 223, no. 1, pp. 143–
150, 2005.
[58] N. Benachenhou, S. Guiral, I. Gorska-Flipot, D. Labuda, and D.
Sinnett, “Frequent loss of heterozygosity at the DNAmismatch-
repair loci hMLH1 and hMSH3 in sporadic breast cancer,”
British Journal of Cancer, vol. 79, no. 7-8, pp. 1012–1017, 1999.
[59] P. Chacko, B. Rajan, T. Joseph, B. S. Mathew, and M. Radhakr-
ishna Pillai, “Polymorphisms in DNA repair gene XRCC1 and
increased genetic susceptibility to breast cancer,” Breast Cancer
Research and Treatment, vol. 89, no. 1, pp. 15–21, 2005.
[60] M.Majidinia andB. Yousefi, “DNA repair and damage pathways
in breast cancer development and therapy,”DNARepair, vol. 54,
pp. 22–29, 2017.
[61] F. Shah, D. Logsdon, R. A. Messmann, J. C. Fehrenbacher, M.
L. Fishel, and M. R. Kelley, “Exploiting the Ref-1-APE1 node in
cancer signaling and other diseases: from bench to clinic,” npj
Precision Oncology, vol. 1, no. 1, article no 19, 2017.
[62] H. S. Rugo, J.-P. Delord, S.-A. Im et al., “Safety and anti-
tumor activity of pembrolizumab in patients with estrogen
receptor–positive/human epidermal growth factor receptor
2–negative advanced breast cancer,” Clinical Cancer Research,
vol. 24, no. 12, pp. 2804–2811, 2018.
[63] S. Adams, P. Schmid, H. S. Rugo et al., “Pembrolizumab
monotherapy for previously treated metastatic triple-negative
breast cancer: cohort A of the phase II KEYNOTE-086 study,”
Annals of Oncology, vol. 30, no. 3, pp. 397–404, 2019.
[64] R. Nanda, L. Q. M. Chow, E. C. Dees et al., “Pembrolizumab in
patients with advanced triple-negative breast cancer: Phase Ib
keynote-012 study,” Journal of Clinical Oncology, vol. 34, no. 21,
pp. 2460–2467, 2016.
[65] C. Solinas, A. Gombos, S. Latifyan, M. Piccart-Gebhart, M.
Kok, and L. Buisseret, “Targeting immune checkpoints in breast
cancer: an update of early results,” ESMO Open, vol. 2, no. 5,
Article ID e000255, 2017.
[66] J. M. Garc´ıa, A. Llombart, J. L. Alonso et al., “Abstract CT152:
A phase II study of pembrolizumab and eribulin in patients
with HR-positive/HER2-negative metastatic breast cancer pre-
viously treatedwith anthracyclines and taxanes (KELLY study),”
Cancer Research, vol. 78, supplement 13, Article ID CT152, 2018.
[67] L. J. Esserman, D. A. Berry, A. DeMichele et al., “Patho-
logic complete Response Predicts Recurrence-Free Survival
More Effectively by Cancer Subset: Results From the I-SPY
1 TRIAL—CALGB 150007/150012, ACRIN 6657,” Journal of
Clinical Oncology, vol. 30, no. 26, pp. 3242–3249, 2012.
[68] P. Schmid, Y.H. Park, E.Mun˜oz-Couselo et al., “Pembrolizumab
(pembro) + chemotherapy (chemo) as neoadjuvant treatment
for triple negative breast cancer (TNBC): preliminary results
from KEYNOTE-173,” Journal of Clinical Oncology, vol. 35,
article no 556, supplement 15, 2017.
[69] S. Loibl, M. Untch, N. Burchardi et al., “Randomized phase II
neoadjuvant study (GeparNuevo) to investigate the addition of
durvalumab to a taxane-anthracycline containing chemother-
apy in triple negative breast cancer (TNBC),” Journal of Clinical
Oncology, vol. 36, article no 104, supplement 15, 2018.
[70] S. Domchek, S. Postel-Vinay, S. Im et al., “Abstract OT3-
05-03: MEDIOLA: an open-label, phase I/II basket study
of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1
antibody)–Additional breast cancer cohorts,” Cancer Research,
vol. 79, supplement 4, Article ID OT3-05-03, 2019.
[71] L. A. Emens, C. Cruz, J. P. Eder et al., “Long-term clinical
outcomes and biomarker analyses of atezolizumab therapy for
patients with metastatic triple-negative breast cancer,” JAMA
Oncology, vol. 5, no. 1, article no 74, 2019.
[72] S. Verma, D. Miles, L. Gianni et al., “Trastuzumab emtansine
for HER2-positive advanced breast cancer,” The New England
Journal of Medicine, vol. 367, no. 19, pp. 1783–1791, 2012.
[73] K. Khoury, C. Isaacs, M. Gatti-Mays et al., “Abstract OT3-04-01:
Nivolumab or capecitabine or combination therapy as adjuvant
therapy for triple negative breast cancer (TNBC) with residual
disease following neoadjuvant chemotherapy:TheOXEL study,”
Cancer Research, vol. 79, supplement 4, Article ID OT3-04-01,
2019.
[74] C. Omarini, G. Guaitoli, S. Pipitone et al., “Neoadjuvant
treatments in triple-negative breast cancer patients: where we
are now and where we are going,” Cancer Management and
Research, vol. 10, pp. 91–103, 2018.
[75] L. Y. Dirix, I. Takacs, G. Jerusalem et al., “Avelumab, an anti-
PD-L1 antibody, in patients with locally advanced or metastatic
breast cancer: A phase 1b JAVELIN solid tumor study,” Breast
Cancer Research andTreatment, vol. 167, no. 3, pp. 671–686, 2018.
[76] K. Oualla, H. M. El-Zawahry, B. Arun et al., “Novel therapeutic
strategies in the treatment of triple-negative breast cancer,”
Therapeutic Advances inMedical Oncology, vol. 9, no. 7, pp. 493–
511, 2017.
[77] J. Abdo, D. L. Cornell, S. K. Mittal, and D. K. Agrawal,
“Immunotherapy plus cryotherapy: potential augmented
abscopal effect for advanced cancers,” Frontiers in Oncology,
vol. 8, article no 85, 2018.
[78] D. Robinson, E. M. Van Allen, and Y.-M. Wu, “Integrative
clinical genomics of advanced prostate cancer,” Cell, vol. 161, no.
5, pp. 1215–1228, 2015.
[79] Y. A. Wang, J. Jian, C. Hung et al., “Germline breast cancer
susceptibility gene mutations and breast cancer outcomes,”
BMC Cancer, vol. 18, no. 1, article no 315, 2018.
[80] Network TCGAR, “Integrated genomic analyses of ovarian
carcinoma,” Nature, vol. 474, no. 7353, pp. 609–615, 2011.
[81] R. P. Kaur, G. Shafi, R. P. Benipal, and A.Munshi, “Frequency of
pathogenic germlinemutations in cancer susceptibility genes in
breast cancer patients,” Medical Oncology, vol. 35, no. 6, article
no 81, 2018.
[82] Y. Shen, Y.-H. Lee, J. Panneerselvam, J. Zhang, L.W.M. Loo, and
P. Fei, “Mutated fanconi anemia pathway in non-fanconi anemia
cancers,” Oncotarget, vol. 6, no. 24, pp. 20396–20403, 2015.
[83] M. Esteller, J. M. Silva, G. Dominguez et al., “Promoter hyper-
methylation and BRCA1 inactivation in sporadic breast and
ovarian tumors,” Journal of the National Cancer Institute, vol.
92, no. 7, pp. 564–569, 2000.
[84] A. Potapova, A. M. Hoffman, A. K. Godwin, T. Al-Saleem,
and P. Cairns, “Promoter hypermethylation of the PALB2
susceptibility gene in inherited and sporadic breast and ovarian
cancer,” Cancer Research, vol. 68, no. 4, pp. 998–1002, 2008.
[85] T. Hansmann, G. Pliushch, M. Leubner et al., “Constitutive
promoter methylation of BRCA1 and RAD51C in patients with
familial ovarian cancer and early-onset sporadic breast cancer,”
HumanMolecular Genetics, vol. 21, no. 21, pp. 4669–4679, 2012.
[86] M. Wei, J. Xu, J. Dignam et al., “Estrogen receptor 𝛼, BRCA1,
and FANCF promoter methylation occur in distinct subsets of
sporadic breast cancers,” Breast Cancer Research and Treatment,
vol. 111, no. 1, pp. 113–120, 2008.
[87] C. J. Lord and A. Ashworth, “BRCAness revisited,” Nature
Reviews Cancer, vol. 16, no. 2, pp. 110–120, 2016.
12 Journal of Oncology
[88] N. Riaz, P. Blecua, R. S. Lim et al., “Pan-cancer analysis of bi-
allelic alterations in homologous recombination DNA repair
genes,”Nature Communications, vol. 8, no. 1, article no 857, 2017.
[89] J. M. Mulligan, L. A. Hill, S. Deharo et al., “Identification
and validation of an anthracycline/cyclophosphamide-based
chemotherapy response assay in breast cancer,” Journal of the
National Cancer Institute, vol. 106, no. 1, Article ID djt335, 2014.
[90] E. E. Parkes, S. M. Walker, L. E. Taggart et al., “Activation
of STING-dependent innate immune signaling By S-phase-
specific DNA damage in breast cancer,” Journal of the National
Cancer Institute, vol. 109, no. 1, Article ID djw199, 2016.
[91] S. R. Lakhani, J. Jacquemier, J. P. Sloane et al., “Multifactorial
analysis of differences between sporadic breast cancers and
cancers involving BRCA1 and BRCA2mutations,” Journal of the
National Cancer Institute, vol. 90, no. 15, pp. 1138–1145, 1998.
[92] A. L. Bane, J. C. Beck, I. Bleiweiss et al., “BRCA2 mutation-
associated breast cancers exhibit a distinguishing phenotype
based on morphology and molecular profiles from tissue
microarrays,” The American Journal of Surgical Pathology, vol.
31, no. 1, pp. 121–128, 2007.
[93] C.DelloRusso, P. L.Welcsh,W.Wang, R. L. Garcia,M.King, and
E. M. Swisher, “Functional characterization of a novel BRCA1-
null ovarian cancer cell line in response to ionizing radiation,”
Molecular Cancer Research, vol. 5, no. 1, pp. 35–45, 2007.
[94] H. Xu, J. Xian, E. Vire et al., “Up-regulation of the interferon-
related genes in BRCA2 knockout epithelial cells,” The Journal
of Pathology, vol. 234, no. 3, pp. 386–397, 2014.
[95] X. Ma, K. Norsworthy, N. Kundu et al., “CXCR3 expression is
associated with poor survival in breast cancer and promotes
metastasis in a murine model,” Molecular Cancer Therapeutics,
vol. 8, no. 3, pp. 490–498, 2009.
[96] A. A. Ejaeidi, B. S. Craft, L. V. Puneky, R. E. Lewis, and J. M.
Cruse, “Hormone receptor-independent CXCL10 production
is associated with the regulation of cellular factors linked to
breast cancer progression and metastasis,” Experimental and
Molecular Pathology, vol. 99, no. 1, pp. 163–172, 2015.
[97] Y. J. Ku, H. H. Kim, J. H. Cha et al., “Predicting the level of
tumor-infiltrating lymphocytes in patients with triple-negative
breast cancer: Usefulness of breast MRI computer-aided detec-
tion and diagnosis,” Journal of Magnetic Resonance Imaging, vol.
47, no. 3, pp. 760–766, 2018.
[98] C. Herrero-Vicent, A. Guerrera, J. Gavila´ et al., “Predictive and
prognostic impact of tumor-infiltrating lymphocytes in triple-
negative breast cancer treated with neoadjuvant chemotherapy,”
ecancermedicalscience, vol. 11, article no 759, 2017.
[99] P. Savas, R. Salgado, C. Denkert et al., “Clinical relevance of
host immunity in breast cancer: from TILs to the clinic,”Nature
Reviews Clinical Oncology, vol. 13, no. 4, pp. 228–241, 2016.
[100] S. Loi, N. Sirtaine, F. Piette et al., “Prognostic and predictive
value of tumor-infiltrating lymphocytes in a phase III ran-
domized adjuvant breast cancer trial in node-positive breast
cancer comparing the addition of docetaxel to doxorubicin
with doxorubicin-based chemotherapy: BIG 02-98,” Journal of
Clinical Oncology, vol. 31, no. 7, pp. 860–867, 2013.
[101] A. Balsari, A. Merlo, P. Casalini et al., “FOXP3 expression and
overall survival in breast cancer,” Journal of Clinical Oncology,
vol. 27, no. 11, pp. 1746–1752, 2009.
[102] N. R. West, S. E. Kost, S. D. Martin et al., “Tumor-infiltrating
FOXP3(+) lymphocytes are associated with cytotoxic immune
responses and good clinical outcome in oestrogen receptor-
negative breast cancer,” British Journal of Cancer, vol. 108, no.
1, pp. 155–162, 2013.
[103] B. Weigelt, R. Bi, R. Kumar et al., “The landscape of somatic
genetic alterations in breast cancers from ATM germline muta-
tion carriers,” JNCI: Journal of the National Cancer Institute, vol.
110, no. 9, pp. 1030–1034, 2018.
[104] G. Landskron, M. De la Fuente, P. Thuwajit, C. Thuwajit, and
M. A. Hermoso, “Chronic inflammation and cytokines in the
tumor microenvironment,” Journal of Immunology Research,
vol. 2014, Article ID 149185, 19 pages, 2014.
[105] P. Allavena, A. Sica, G. Solinas, C. Porta, and A. Mantovani,
“The inflammatory micro-environment in tumor progression:
The role of tumor-associated macrophages,” Critical Review in
Oncology/Hematology, vol. 66, no. 1, pp. 1–9, 2008.
[106] I. S. Pateras, S. Havaki, X. Nikitopoulou et al., “The DNA
damage response and immune signaling alliance: Is it good
or bad? Nature decides when and where,” Pharmacology &
Therapeutics, vol. 154, pp. 36–56, 2015.
[107] H. Ishikawa and G. N. Barber, “STING is an endoplasmic
reticulum adaptor that facilitates innate immune signalling,”
Nature, vol. 455, no. 7213, pp. 674–678, 2008.
[108] A. Ha¨rtlova, S. F. Erttmann, F. A. M. Raffi et al., “DNA damage
primes the type i interferon systemvia the cytosolicDNAsensor
STING to promote anti-microbial innate immunity,” Immunity,
vol. 42, no. 2, pp. 332–343, 2015.
[109] S. M. Harding, J. L. Benci, J. Irianto, D. E. Discher, A. J.
Minn, and R. A. Greenberg, “Mitotic progression following
DNA damage enables pattern recognition within micronuclei,”
Nature, vol. 548, no. 7668, pp. 466–470, 2017.
[110] K. J. MacKenzie, P. Carroll, C.-A. Martin et al., “CGAS
surveillance of micronuclei links genome instability to innate
immunity,” Nature, vol. 548, no. 7668, pp. 461–465, 2017.
[111] L. Sun, J. Wu, F. Du, X. Chen, and Z. J. Chen, “Cyclic GMP-
AMP synthase is a cytosolic DNA sensor that activates the type
I interferon pathway,” Science, vol. 339, no. 6121, pp. 786–791,
2013.
[112] J. Wu, L. Sun, X. Chen et al., “Cyclic GMP-AMP is an endoge-
nous secondmessenger in innate immune signaling by cytosolic
DNA,” Science, vol. 339, no. 6121, pp. 826–830, 2013.
[113] T. Li and Z. J. Chen, “The cGAS–cGAMP–STING pathway con-
nects DNA damage to inflammation, senescence, and cancer,”
The Journal of Experimental Medicine, vol. 215, no. 5, pp. 1287–
1299, 2018.
[114] L. Corrales, V. Matson, B. Flood, S. Spranger, and T. F.
Gajewski, “Innate immune signaling and regulation in cancer
immunotherapy,” Cell Research, vol. 27, no. 1, pp. 96–108, 2017.
[115] J. Ahn, T. Xia, H. Konno, K. Konno, P. Ruiz, and G. N. Bar-
ber, “Inflammation-driven carcinogenesis is mediated through
STING,” Nature Communications, vol. 5, article no 5166, 2014.
[116] L. Deng, H. Liang, M. Xu et al., “STING-dependent cytosolic
DNA sensing promotes radiation-induced type I interferon-
dependent antitumor immunity in immunogenic tumors,”
Immunity, vol. 41, no. 5, pp. 543–852, 2014.
[117] R. D. Wilkinson, D. I. Johnston, E. E. Parkes, N. McCabe,
and R. D. Kennedy, “Abstract 3787: exploring the effect of
chemotherapies on STING-dependent cytokine release,”Cancer
Research, vol. 78, Supplement 13, Article ID 3787, 2018.
[118] K. J. Harrington, J. Brody, M. Ingham et al., “LBA15Preliminary
results of the first-in-human (FIH) study of MK-1454, an ago-
nist of stimulator of interferon genes (STING), as monotherapy
or in combination with pembrolizumab (pembro) in patients
with advanced solid tumors or lymphomas,”Annals ofOncology,
vol. 29, supplement 8, Article ID mdy424.015, 2018.
Journal of Oncology 13
[119] S. Iurescia, D. Fioretti, and M. Rinaldi, “Targeting Cytosolic
Nucleic Acid-Sensing Pathways for Cancer Immunotherapies,”
Frontiers in Immunology, vol. 9, article no 711, 2018.
[120] D. R. Ranoa, A. D. Parekh, S. P. Pitroda et al., “Cancer therapies
activate RIG-I-like receptor pathway through endogenous non-
coding RNAs,”Oncotarget, vol. 7, no. 18, pp. 26496–26515, 2016.
[121] K. Ku¨bler, N. Gehrke, S. Riemann et al., “Targeted activation
of RNA helicase retinoic acid–inducible gene-i induces proim-
munogenic apoptosis of human ovarian cancer cells,” Cancer
Research, vol. 70, no. 13, pp. 5293–5304, 2010.
[122] J. Fu, D. B. Kanne, M. Leong et al., “STING agonist formulated
cancer vaccines can cure established tumors resistant to PD-1
blockade,” Sci Transl Med, vol. 7, no. 283, Article ID 283ra52,
2015.
[123] L. Corrales, L. H. Glickman, S. M. McWhirter et al., “Direct
activation of STING in the tumor microenvironment leads
to potent and systemic tumor regression and immunity,” Cell
Reports, vol. 11, no. 7, pp. 1018–1030, 2015.
[124] H. Liang, L. Deng, Y. Hou et al., “Host STING-dependent
MDSC mobilization drives extrinsic radiation resistance,”
Nature Communications, vol. 8, no. 1, article no 1736, 2017.
[125] H. Zhu, Y. Gu, Y. Xue, M. Yuan, X. Cao, and Q. Liu, “CXCR2+
MDSCs promote breast cancer progression by inducing EMT
and activated T cell exhaustion,” Oncotarget, vol. 8, no. 70, pp.
114554–114567, 2017.
[126] S. Glu¨ck, B. Guey, M. F. Gulen et al., “Innate immune sensing
of cytosolic chromatin fragments through cGAS promotes
senescence,” Nature Cell Biology, vol. 19, no. 9, pp. 1061–1070,
2017.
[127] Z. Dou, K. Ghosh, M. G. Vizioli et al., “Cytoplasmic chromatin
triggers inflammation in senescence and cancer,” Nature, vol.
550, no. 7676, pp. 402–406, 2017.
[128] H. Yang, H. Wang, J. Ren, Q. Chen, and Z. J. Chen, “cGAS is
essential for cellular senescence,” Proceedings of the National
Acadamy of Sciences of the United States of America, vol. 114, no.
23, pp. E4612–E4620, 2017.
[129] S. F. Bakhoum, B. Ngo, A. M. Laughney et al., “Chromosomal
instability drivesmetastasis through a cytosolic DNA response,”
Nature, vol. 553, article no 467, 2018.
[130] D. M. Pardoll, “The blockade of immune checkpoints in cancer
immunotherapy,”Nature Reviews Cancer, vol. 12, no. 4, pp. 252–
264, 2012.
[131] M. Nishino, N. H. Ramaiya, H. Hatabu, and F. S. Hodi, “Moni-
toring immune-checkpoint blockade: Response evaluation and
biomarker development,”Nature Reviews Clinical Oncology, vol.
14, no. 11, pp. 655–668, 2017.
[132] T. F. Gajewski, H. Schreiber, and Y. X. Fu, “Innate and adap-
tive immune cells in the tumor microenvironment,” Nature
Immunology, vol. 14, pp. 1014–1022, 2013.
[133] K.M.Mahoney, P.D. Rennert, andG. J. Freeman, “Combination
cancer immunotherapy and new immunomodulatory targets,”
Nature Reviews Drug Discovery, vol. 14, no. 8, pp. 561–584, 2015.
[134] J. Lee, R. Kefford, and M. Carlino, “PD-1 and PD-L1 inhibitors
in melanoma treatment: past success, present application and
future challenges,” Immunotherapy, vol. 8, no. 6, pp. 733–746,
2016.
[135] L. T. Nguyen and P. S. Ohashi, “Clinical blockade of PD1
and LAG3 — potential mechanisms of action,” Nature Reviews
Immunology, vol. 15, no. 1, pp. 45–56, 2015.
[136] S. Liang, Y. Latchman, J. Buhlmann et al., “Regulation of PD-1,
PD-L1, and PD-L2 expression during normal and autoimmune
responses,” European Journal of Immunology, vol. 33, no. 10, pp.
2706–2716, 2003.
[137] X. Wang, F. Teng, L. Kong, and J. Yu, “PD-L1 expression in
human cancers and its association with clinical outcomes,”
OncoTargets and Therapy, pp. 5023–5039, 2016.
[138] M. Z. Baptista, L. O. Sarian, S. F.M. Derchain, G. A. Pinto, and J.
Vassallo, “Prognostic significance of PD-L1 and PD-L2 in breast
cancer,” Human Pathology, vol. 47, no. 1, pp. 78–84, 2016.
[139] J. He, Y. Hu, M. Hu, and B. Li, “Development of PD-1/PD-L1
pathway in tumor immune microenvironment and treatment
for non-small cell lung cancer,” Scientific Reports, vol. 5, no. 1,
Article ID 13110, 2015.
[140] D. G. Brooks, S. Ha, H. Elsaesser, A. H. Sharpe, G. J. Freeman,
and M. B. Oldstone, “IL-10 and PD-L1 operate through distinct
pathways to suppress T-cell activity during persistent viral
infection,” Proceedings of the National Acadamy of Sciences of
the United States of America, vol. 105, no. 51, pp. 20428–20433,
2008.
[141] H. Guan, Y. Wan, J. Lan et al., “PD-L1 is a critical mediator of
regulatory B cells and T cells in invasive breast cancer,” Scientific
Reports, vol. 6, no. 1, Article ID 35651, 2016.
[142] S. Amarnath, C.W.Mangus, J. C.M.Wang et al., “ThePDL1-PD1
axis converts human TH1 cells into regulatory T cells,” Science
Translational Medicine, vol. 3, no. 111, Article ID 111ra120, 2011.
[143] H. O. Alsaab, S. Sau, R. Alzhrani et al., “PD-1 and PD-L1
checkpoint signaling inhibition for cancer immunotherapy:
mechanism, combinations, and clinical outcome,” Frontiers in
Pharmacology, vol. 8, article no. 561, 2017.
[144] F. Bertucci andA.Gonc¸alves, “Immunotherapy in breast cancer:
the emerging role of PD-1 and PD-L1,” Current Oncology
Reports, vol. 19, no. 10, article no 64, 2017.
[145] M.M. Boyiadzis, J. M. Kirkwood, J. L. Marshall, C. C. Pritchard,
N. S. Azad, and J. L. Gulley, “Significance and implications
of FDA approval of pembrolizumab for biomarker-defined
disease,” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1,
article no 35, 2018.
[146] T. A. Chan,M. Yarchoan, E. Jaffee et al., “Development of tumor
mutation burden as an immunotherapy biomarker: utility for
the oncology clinic,” Annals of Oncology, vol. 30, no. 1, pp. 44–
56, 2019.
[147] M. W. Audeh, F. Dadmanesh, and J. Yearley, “Abstract P4-04-
01: PDL-1 expression in primary breast cancers with germline
mutations in BRCA 1 and 2,” Cancer Research, vol. 76,
supplement 4, Article ID P-P4-04-01, 2016, http://cancerres
.aacrjournals.org/content/76/4 Supplement/P4-04-01.abstract.
[148] D. Samanta, Y. Park, X. Ni et al., “ Chemotherapy induces
enrichment of CD47 + /CD73 + /PDL1 + immune evasive
triple-negative breast cancer cells ,” Proceedings of the National
Acadamy of Sciences of the United States of America, vol. 115, no.
6, pp. E1239–E1248, 2018.
[149] S. Adams, M. E. Gatti-Mays, K. Kalinsky et al., “Current
landscape of immunotherapy in breast cancer,” JAMAOncology,
2019.
[150] Y. Wang, S. Zhou, F. Yang et al., “Treatment-related adverse
events of PD-1 and PD-L1 inhibitors in clinical trialsa systematic
review and meta-analysis,” JAMA Oncology, 2019.
[151] R. Plummer, C. Jones, M. Middleton et al., “Phase i study
of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in
combination with temozolomide in patients with advanced
solid tumors,” Clinical Cancer Research, vol. 14, no. 23, pp. 7917–
7923, 2008.
14 Journal of Oncology
[152] H. Farmer, H. McCabe, C. J. Lord et al., “Targeting the DNA
repair defect in BRCA mutant cells as a therapeutic strategy,”
Nature, vol. 434, no. 7035, pp. 917–921, 2005.
[153] H. E. Bryant, N. Schultz, H. D.Thomas et al., “Specific killing of
BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)
polymerase,” Nature, vol. 434, no. 7035, pp. 913–917, 2005.
[154] M. Robson, S. Im, E. Senkus et al., “Olaparib for metastatic
breast cancer in patients with a germline BRCA mutation,”The
New England Journal of Medicine, vol. 377, no. 6, pp. 523–533,
2017.
[155] J. K. Litton, H. S. Rugo, J. Ettl et al., “Talazoparib in patients with
advanced breast cancer and a germline BRCA mutation,” The
New England Journal of Medicine, vol. 379, no. 8, pp. 753–763,
2018.
[156] R. A. Stewart, P. G. Pilie´, and T. A. Yap, “Development of
PARP and immune-checkpoint inhibitor combinations,” Can-
cer Research, vol. 78, no. 24, pp. 6717–6725, 2018.
[157] J. Shen, W. Zhao, Z. Ju et al., “PARPi triggers the STING-
dependent immune response and enhances the therapeu-
tic efficacy of immune checkpoint blockade independent of
BRCAness,” Cancer Research, vol. 79, no. 2, pp. 311–319, 2019.
[158] T. Sen, B. L. Rodriguez, L. Chen et al., “Targeting DNA damage
response promotes anti-tumor immunity through STING-
mediated T-cell activation in small cell lung cancer,” Cancer
Discovery, vol. 9, no. 5, Article ID CD-18-1020, pp. 646–661,
2019.
[159] R. M. Chabanon, G. Muirhead, D. B. Krastev et al., “PARP
inhibition enhances tumor cell–intrinsic immunity in ERCC1-
deficient non–small cell lung cancer,” The Journal of Clinical
Investigation, vol. 129, no. 3, pp. 1211–1228, 2019.
[160] C. Pantelidou, O. Sonzogni, M. De Oliveria Taveira et al.,
“PARP inhibitor efficacy depends on CD8+ T cell recruitment
via intratumoral STING pathway activation in BRCA-deficient
models of triple-negative breast cancer,” Cancer Discovery, vol.
9, no. 6, Article ID CD-18-1218, pp. 722–737, 2019.
[161] S. Domchek, S. Postel-Vinay, Y. Bang et al., “Abstract PD6-11: an
open-label, multitumor, phase II basket study of olaparib and
durvalumab (MEDIOLA): results in germline BRCA-mutated
(g BRCA m) HER2-negative metastatic breast cancer (MBC),”
Cancer Research, vol. 78, supplement 4, Article ID PD6-11, 2018.
[162] S. Vinayak, S. Tolaney, L. Schwartzberg et al., “bstract PD5-02:
durability of clinical benefit with niraparib + pembrolizumab
in patients with advanced triple-negative breast cancer beyond
BRCA: (TOPACIO/Keynote-162),” Cancer Research, vol. 79,
supplement 4, Article ID PD5-02, 2019.
[163] D. Fukumura, J. Kloepper, Z. Amoozgar, D. G. Duda, and R. K.
Jain, “Enhancing cancer immunotherapy using antiangiogenics:
opportunities and challenges,” Nature Reviews Clinical Oncol-
ogy, vol. 15, no. 5, pp. 325–340, 2018.
[164] K. W. Mouw, M. S. Goldberg, P. A. Konstantinopoulos, and
A. D. D’Andrea, “DNA damage and repair biomarkers of
immunotherapy response,” Cancer Discovery, vol. 7, no. 7, pp.
675–693, 2017.
[165] V. G. Gorgoulis and T. D. Halazonetis, “Oncogene-induced
senescence: the bright and dark side of the response,” Current
Opinion in Cell Biology, vol. 22, no. 6, pp. 816–827, 2010.
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
